• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tofacitinib Is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.

作者信息

Gilmore Robert, Hilley Patrick, Srinivasan Ashish, Choy Matthew C, Grace Josephine A, de Cruz Peter

机构信息

Department of Gastroenterology, Austin Health, Melbourne, Australia.

Department of Gastroenterology, Austin Health, Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.

出版信息

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1302-1303. doi: 10.1016/j.cgh.2020.07.046. Epub 2020 Nov 26.

DOI:10.1016/j.cgh.2020.07.046
PMID:33248087
Abstract
摘要

相似文献

1
Tofacitinib Is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.托法替布与英夫利昔单抗联合使用治疗难治性溃疡性结肠炎时安全有效。
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1302-1303. doi: 10.1016/j.cgh.2020.07.046. Epub 2020 Nov 26.
2
Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis.环孢素和托法替尼联合治疗在一例严重激素抵抗溃疡性结肠炎患者中的成功应用。
Inflamm Bowel Dis. 2021 Nov 15;27(12):e157-e158. doi: 10.1093/ibd/izab181.
3
Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
Gastroenterol Hepatol. 2022 Apr;45 Suppl 1:11-12. doi: 10.1016/j.gastrohep.2021.05.005. Epub 2021 Jun 9.
4
Efficacy of tofacitinib treatment in ulcerative colitis.托法替布治疗溃疡性结肠炎的疗效。
Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14.
5
Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.托法替尼治疗急性重度溃疡性结肠炎的补救治疗：真实世界经验。
J Crohns Colitis. 2020 Jul 30;14(7):1026-1028. doi: 10.1093/ecco-jcc/jjaa018.
6
TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.托法替布用于治疗对抗肿瘤坏死因子和抗整合素疗法难治的溃疡性结肠炎
Arq Gastroenterol. 2018 Apr-Jun;55(2):198-200. doi: 10.1590/S0004-2803.201800000-36.
7
Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.在慢性活动性溃疡性结肠炎中使用生物制剂托法替布联合靶向治疗
Inflamm Bowel Dis. 2021 Aug 19;27(9):e105-e106. doi: 10.1093/ibd/izab095.
8
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.托法替布作为挽救疗法用于 55 例难治性重度溃疡性结肠炎住院患者：GETAID 队列研究。
Aliment Pharmacol Ther. 2021 Aug;54(3):312-319. doi: 10.1111/apt.16463. Epub 2021 Jun 20.
9
Nonbiologic Immune Suppression in Ulcerative Colitis.溃疡性结肠炎的非生物免疫抑制。
Gastroenterol Clin North Am. 2020 Dec;49(4):731-738. doi: 10.1016/j.gtc.2020.07.003. Epub 2020 Sep 19.
10
Combination Tofacitinib and Calcineurin Inhibitor in the Management of Treatment-Refractory Ulcerative Colitis May Be Effective, But Is It Necessary?
Inflamm Bowel Dis. 2022 Mar 30;28(4):e46. doi: 10.1093/ibd/izab356.

引用本文的文献

1
Dual Therapy in Inflammatory Bowel Disease.炎症性肠病的双重疗法
Biomolecules. 2025 Feb 3;15(2):222. doi: 10.3390/biom15020222.
2
Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis.应对治疗抵抗：用于溃疡性结肠炎的 Janus 激酶抑制剂
World J Clin Cases. 2024 Aug 26;12(24):5468-5472. doi: 10.12998/wjcc.v12.i24.5468.
3
Precision therapy for ulcerative colitis: insights from mitochondrial dysfunction interacting with the immune microenvironment.溃疡性结肠炎的精准治疗：线粒体功能障碍与免疫微环境相互作用的见解。
Front Immunol. 2024 Jul 4;15:1396221. doi: 10.3389/fimmu.2024.1396221. eCollection 2024.
4
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.双重靶向治疗部分或无应答炎症性肠病的疗效和安全性：文献系统评价。
Dig Dis Sci. 2023 Jun;68(6):2604-2623. doi: 10.1007/s10620-023-07837-0. Epub 2023 Feb 20.
5
Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease.维多珠单抗与其他生物制剂或托法替布联合治疗炎症性肠病的良好结局
Crohns Colitis 360. 2021 Jun 9;3(3):otab030. doi: 10.1093/crocol/otab030. eCollection 2021 Jul.